- Home
- SDGR vs VCEL Comparison
SDGR vs VCEL Comparison
Compare SDGR & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDGR
- VCEL
- Stock Information
- Founded
- SDGR 1990
- VCEL 1989
- Country
- SDGR United States
- VCEL United States
- Employees
- SDGR N/A
- VCEL N/A
- Industry
- SDGR Biotechnology: Pharmaceutical Preparations
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SDGR Health Care
- VCEL Health Care
- Exchange
- SDGR Nasdaq
- VCEL Nasdaq
- Market Cap
- SDGR 1.8B
- VCEL 2.1B
- IPO Year
- SDGR 2020
- VCEL 1997
- Fundamental
- Price
- SDGR $23.91
- VCEL $41.73
- Analyst Decision
- SDGR Buy
- VCEL Strong Buy
- Analyst Count
- SDGR 5
- VCEL 8
- Target Price
- SDGR $32.80
- VCEL $61.75
- AVG Volume (30 Days)
- SDGR 1.5M
- VCEL 517.5K
- Earning Date
- SDGR 05-07-2025
- VCEL 05-08-2025
- Dividend Yield
- SDGR N/A
- VCEL N/A
- EPS Growth
- SDGR N/A
- VCEL 521.85
- EPS
- SDGR N/A
- VCEL 0.05
- Revenue
- SDGR $230,492,000.00
- VCEL $238,541,000.00
- Revenue This Year
- SDGR $24.12
- VCEL $23.23
- Revenue Next Year
- SDGR $18.60
- VCEL $24.41
- P/E Ratio
- SDGR N/A
- VCEL $800.69
- Revenue Growth
- SDGR 22.29
- VCEL 14.80
- 52 Week Low
- SDGR $16.60
- VCEL $37.39
- 52 Week High
- SDGR $28.47
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- SDGR 49.40
- VCEL 51.56
- Support Level
- SDGR $22.69
- VCEL $37.48
- Resistance Level
- SDGR $24.92
- VCEL $39.42
- Average True Range (ATR)
- SDGR 1.38
- VCEL 1.84
- MACD
- SDGR -0.33
- VCEL 0.57
- Stochastic Oscillator
- SDGR 26.64
- VCEL 77.71
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.